scholarly journals Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis

2017 ◽  
Vol 2 ◽  
pp. 131-137 ◽  
Author(s):  
Bartłomiej Kwiek ◽  
Joanna Narbutt ◽  
Anna Sysa-Jędrzejowska ◽  
Andrzej Langner ◽  
Aleksandra Lesiak
Keyword(s):  
Platelet Activation ◽  
Plaque Psoriasis ◽  
Term Treatment ◽  
Chronic Plaque Psoriasis ◽  
Biological Drugs ◽  
Long Term Treatment

Long-term treatment of chronic plaque psoriasis with calcipotriol

1993 ◽  
Vol 4 (4) ◽  
pp. 173-177 ◽  
Author(s):  
T Poyner ◽  
Iw Hughes ◽  
Bk Dass ◽  
Pi Adnitt
Keyword(s):  
Plaque Psoriasis ◽  
Term Treatment ◽  
Chronic Plaque Psoriasis ◽  
Long Term Treatment

Long-term treatment of plaque psoriasis with efalizumab: an Italian experience

2007 ◽  
Vol 156 (s2) ◽  
pp. 17-23 ◽  
Author(s):  
A. Costanzo ◽  
K. Peris ◽  
M. Talamonti ◽  
A. Di Cesare ◽  
M. Concetta Fargnoli ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Term Treatment ◽  
Italian Experience ◽  
Long Term Treatment

26260 Long-term treatment of plaque psoriasis with Cal/BD foam was locally well tolerated and not associated with skin atrophy

2021 ◽  
Vol 85 (3) ◽  
pp. AB92
Author(s):  
Leon Kircik ◽  
Marie Holst Mørch ◽  
Bibi Petersen ◽  
Monika Liljedahl ◽  
Andreas Wollenberg
Keyword(s):  
Plaque Psoriasis ◽  
Term Treatment ◽  
Skin Atrophy ◽  
Long Term Treatment

scholarly journals A Case Study on Plaque Psoriasis with Ayurvedic Management

2020 ◽  
Vol 11 (2) ◽  
pp. 342-345
Author(s):  
Pooja P Thakre ◽  
Sourabh Deshmukh ◽  
Vinod Ade
Keyword(s):  
Plaque Psoriasis ◽  
Skin Disease ◽  
Signs And Symptoms ◽  
Term Treatment ◽  
Fish Scale ◽  
Long Term Treatment ◽  
Chronic Skin ◽  
Almost All

Skin disease is one among Deerghkalinvyadhi (Chronic disease) and also one of the AsthaMahagada (Eight dreadful diseases). The disease psoriasis comes under the Kustha roga. Psoriasis is one of the most common dermatologic disorder and a chronic skin disorder of present day. Almost all the skin disease is explained under Kushta- Rogadhikara (skin disease) and classified as MahaKushta and Kshudra Kushta (Major and Minor skin disease). Acharya have described that all Kushta’s have Tri Dosha (three energies) involvement but the type of Kushta depends on the predominance of particular Doshas. The signs and symptoms of Eka-Kushta (psoriasis) in Ayurveda are similar to that of psoriasis explained in modern medicines. Psoriasis is marked by periodic flare-ups of sharply defined red patches, covered by a silvery, flaky surface. Aswedana (Absence of perspiration), Mahavastu (Present all over body), MastyaShakalopama (Look like a fish scale) is the feature mentioned by Acharyas for Eka-kushta. In Psoriasis relapsing nature is most common, which suggests that it needs long term treatment. In modern there is no such treatment for psoriasis. Here is the case of 52 yrs old male patient diagnosed as Plaque psoriasis undergone treatment of Shodhan (Purification) i.e. Vaman (Emesis) as well as Shaman Chikitsa (Palitative treatment) having marked improvement. The study showed that combination of Ayurvedic modalities gives significant result in lakshnas (Symptoms) like Aswedana, Mahavastu, MastyaShakalopama.

Efficacy and Safety of Long-Term Treatment with the LSD1 Inhibitor RN-1 to Increase HbF in Normal, Non-Anemic Baboons

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 324-324
Author(s):  
Kestis Vaitkus ◽  
Vinzon Ibanez ◽  
Robert E Molokie ◽  
Angela Rivers ◽  
Joseph DeSimone ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Platelet Activation ◽  
Sickle Cell ◽  
Term Treatment ◽  
Post Treatment ◽  
Cell Disease ◽  
Long Term Treatment ◽  
F Cells ◽  
Pre Treatment

Abstract Increased levels of fetal hemoglobin (HbF) lessen the severity of symptoms and increase the life span of patients with sickle cell disease. New and more effective strategies to increase HbF are needed because current therapies are ineffective in a significant proportion of patients. The lysine-specific demethylase, LSD1, an enzyme that demethylates Histone H3 mono- and dimethyl- K4 and K9 residues, is a component of the DRED co-repressor complex that represses the γ-globin gene (Cui et al, Mol Cell Biol 31:3298, 2011). Our laboratory has recently shown that RN-1, a pharmacological inhibitor of LSD1, increases γ-globin expression in sickle cell disease (SCD) transgenic mice (Rivers et al, Exp Hematol 43:546, 2015; Cui et al, Blood 126:386, 2015) and in baboons (Rivers et al, Haematol 101:688, 2016), widely acknowledge as the best animal model to test the activity of HbF-inducing drugs. To evaluate the safety and efficacy of RN-1, two normal, non-anemic baboons were treated for an extended period with RN-1 (PA8695, 264d; PA8698, 278d; 0.25mg/kg/d; 5d/wk, sc) and the effect on HbF, F cells, and hematological parameters evaluated weekly. Both animals exhibited weight gain (PA8695: 14.4%; PA8698: 20%) during the course of the study. F retics were increased 8-10 fold by the second week (d9) and were maintained at high levels throughout the course of the study (PA8695: 55.7±17.7% (mean±SD), median (M)=59.0%; PA8698: 56.4±14.5%, M=56.9%). F cell levels increased until d169 and were maintained thereafter at levels 18-25 times greater than pre-treatment (PA8695: 54.5±3.3%, M=54.2%; PA8698: 51.7±3.2%, M=51.4%). HbF levels also increased until d169 and were also maintained thereafter at levels 10-12 times greater than pre-treatment (PA8695: 12.8±1.7%, M=12.1%; PA8698: 11.4±1.4%, M=11.5%). Elevated levels of γ-globin chain synthesis were observed in the peripheral blood on multiple days (d162, d190, d267) of treatment (PA8695, 0.28±0.08 γ/γ+β;PA8698, 0.26±0.08 γ/γ+β). RT-PCR analysis showed that γ-globin mRNA levels were increased 9-22 fold (p<0.01) in FACS-purified CD105+ CD117+/- glyA+ BM erythroid precursor subpopulations of RN-1 treated baboons compared to normal baboons. Absolute neutrophil counts showed no overall decline compared to pre-treatment (PA8695: pre-treatment=2110/μL, post-treatment=3118±1452/μL, M=2765/μL; PA8698: pre-treatment=2690/μL, post-treatment=2936±696/μL, M=2460/μL) although variations were observed. In PA8695 the ANC declined below 1500/μL twice (1490, 1160) and five times (1250, 1410, 1420, 1330, 1000) in PA8595. Monocytes increased 2-3 fold in each animal (PA8695: pre-treatment=100/μL, post-treatment=252±97/μL, M=246/μL; PA8698: pre-treatment=161/μL, post-treatment=425±319/μL, M=347/μL). Hemoglobin (Hb), RBC, and hematocrit (HCT) levels exhibited small overall decreases during the course of treatment but remained within the normal range. Decreases in RBC, Hb, and HCT were associated with blood loss during menstruation (PA8695) and following an accidental laceration of the perineal swelling (PA8698). Rapid recovery was observed in both animals. Significant changes in MCV, MCH, and MCHC during treatment were not observed. Platelet levels decreased approximately 40% in each animal but nevertheless were maintained within the normal range (PA8695: pre-treatment=351 X 103/μL, post-treatment=236±64 X 103/μL, M=219 X 103/μL; PA8698: pre-treatment=224 X 103/μL, post-treatment=143±78 X 103/μL, M=119 X 103/μL). No significant differences in either PT or aPTT assays were observed compared to normal baboons. In vitro platelet activation assays performed to investigate effects on platelet function showed that the fraction of platelets expressing P-selectin (CD62P) on the surface following addition of thrombin was reduced 14% (p<0.02) and the level of CD62P expression reduced 46% (p<0.0001) in RN-1 treated baboons compared to controls. Normal platelet function was restored 10d post-drug. Elevated platelet activation is associated with the pathogenesis of sickle cell disease and inhibitors of platelet activation are currently in clinical trials. We conclude that long-term treatment with RN-1 increases and maintains elevated levels of HbF and F cells in normal baboons and is well-tolerated. Pharmacological inhibitors of LSD1 are therefore likely to be beneficial in patients with SCD. Disclosures Rivers: Acetylon: Research Funding. DeSimone:EpiDestiny: Consultancy, Other: patents around decitabine and tetrahydrouridine. Lavelle:Acetylon: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document